This review discusses the pathophysiology, clinical assessment, and therapeutic strategies for cardiomyopathies with a focus on pediatric patients.
Consolidates knowledge on pediatric cardiomyopathies for clinicians; leaves open gaps requiring prospective pediatric trials.
Cardiomyopathies are diseases of the heart muscle, a term introduced in 1957 to identify a group of myocardial diseases not attributable to coronary artery disease. The definition has since been modified to refer to structural and or functional abnormalities of the myocardium where other known causes of myocardial dysfunction, such as systemic hypertension, valvular disease and ischemic heart disease, have been excluded. In this review, we discuss the pathophysiology, clinical assessment and therapeutic strategies for hypertrophic, dilated and hypertrophic cardiomyopathies, with a particular focus on aspects unique to children.
No takes yet. Share an insight, caveat, or question.
Price et al. (2016) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: